ArticleCancer gene therapy2026
The Tumor-suppressive role of CNTNAP2 in glioma: Dual regulation of the NDN-ERK axis and M2 macrophage polarization.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cancer constitutes a persistent major global health burden, which underscores the urgent demand for innovative biomarkers and therapeutic targets. While the Contactin-associated protein (CNTNAP) family has been associated with tumor development, the pan-cancer role of CNTNAP2 is still poorly characterized. Researchers performed a comprehensive pan-cancer analysis of CNTNAP2 based on The Cancer Genome Atlas (TCGA) datasets to evaluate its expression profile and clinical relevance, and conducted functional experiments in U118MG glioblastoma cells and CNTNAP2-deficient mouse tissues to verify its biological function. The results identified CNTNAP2 as a dual diagnostic (AUC > 0.9) and prognostic biomarker for glioma, with low expression levels correlating to worse overall survival. In vitro assays showed that CNTNAP2 knockdown enhanced the proliferation and migration of U118MG cells, while its overexpression inhibited these malignant phenotypes. Mechanistically, CNTNAP2 deficiency triggered excessive activation of the ERK signaling pathway and downregulated its key downstream target Necdin (NDN), and pharmacological inhibition of ERK reversed the oncogenic effects caused by CNTNAP2 silencing. Further analysis demonstrated elevated M2 macrophage infiltration in glioma, and CNTNAP2 expression was closely correlated with M2 macrophage polarization; high CNTNAP2 expression also corresponded to lower TIDE scores, suggesting improved immunotherapy response. Collectively, CNTNAP2 acts as a tumor suppressor in glioma via the NDN-ERK axis, suppressing tumor progression and M2 macrophage polarization, making it a promising diagnostic, prognostic biomarker and potential therapeutic target for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.